Vitamin A deficiency is an endemic nutrition problem throughout much of the developing world, especially affecting the health and survival of infants, young children, and pregnant and lactating women. These age and life-stage groups represent periods when both nutrition stress is high and diet likely to be chronically deficient in vitamin A. Approximately 127 million preschool-aged children and 7 million pregnant women are vitamin A deficient. Health consequences of vitamin A deficiency include mild to severe systemic effects on innate and acquired mechanisms of host resistance to infection and growth, increased burden of infectious morbidity, mild to severe (blinding) stages of xerophthalmia, and increased risk of mortality. These consequences are defined as vitamin A deficiency disorders (VADD). Globally, 4.4 million preschool children have xerophthalmia and 6 million mothers suffer night blindness during pregnancy. Both conditions are associated with increased risk of morbidity and mortality. While reductions of child mortality of 19-54% following vitamin A treatment have been widely reported, more recent work suggests that dosing newborns with vitamin A may, in some settings, lower infant mortality. Among women, one large trial has so far reported a ≥ 40% reduction in mortality related to pregnancy with weekly, low-dose vitamin A supplementation. Epidemiologic data on vitamin A deficiency disorders can be useful in planning, designing, and targeting interventions.
Introduction
Vitamin A deficiency remains a leading public health problem in the developing world [1] , with its health consequences most apparent and severe among infants, young children, and women of reproductive age. Over the past two decades, tremendous advances have been made in developing indicators of vitamin A status, and defining the magnitude of vitamin A deficiency by region, metabolic and health consequences of deficiency that respond to adequate vitamin A intake, and approaches to effective prevention. Scientific knowledge about vitamin A deficiency and its prevention continues to be translated into effective policies and programs [2] that reflect growing resolve across governments, multilateral and nongovernmental agencies, academia, private industry, and in the community to achieve results.
Successful translation of research into policy and action requires a continuous process of "taking stock," by updating estimates of magnitude in high risk populations, clarifying disease burden associated with vitamin A deficiency, exploring improved prevention through application of epidemiologic advances, and noting promising developments in the field. In this regard, the interested reader is referred to recent, comprehensive supplements that have appeared on vitamin A deficiency and its control 1 as well as to papers that appear elsewhere in this supplement. The present paper addresses the current magnitude of vitamin A deficiency and its array of health disorders in young children and women, as a means to highlight the continued, critical importance of controlling
Prevalence and burden of vitamin A deficiency
Estimates of extent and severity of vitamin A deficiency are imperfect, as they depend on the frequency of use of valid indicators of vitamin A status across populations, and draw on diverse sources of data of varying representativeness. In chronically deficient regions, reports that are based on xerophthalmia in children [3] and night blindness in pregnant women [4] can provide highly specific data on moderateto-severe vitamin A deficiency. Dark adaptometry provides a recently standardized, valid approach to quantify the prevalence of mild scotopic vision loss attributable to vitamin A deficiency [5] but has been insufficiently used to date for estimating burden of deficiency. Stable isotope use allows measurement of total body stores of vitamin A and validation of other indicators of status [6] , while the relative dose response remains a useful research tool for indirectly assessing hepatic retinol adequacy [7] . However, assessing liver or total body stores of vitamin A by these means remains difficult, expensive, and little used in large population studies. Although new and simpler assessment tools are being developed, determination of vitamin A deficiency in most populations rests on interpreting distributions of retinol content of serum or plasma [8, 9] and, among women, also in breast milk [10] . Conjunctival impression cytology (CIC) has also found wide use in assessing population prevalence of vitamin A deficiency [5] , particularly when serologic data could not be collected. These latter measures of status have been used by the World Health Organization (WHO) [11, 12] , the Micronutrient Initiative (MI) [13, 14] , and the International Vitamin A Consultative Group (IVACG) [15] to estimate or monitor changes in the burden of vitamin A deficiency in children and, more recently, estimate the extent of deficiency in pregnant women [15] .
Presently, the IVACG conservatively estimates there to be 127 million vitamin A-deficient preschoolaged children, defined as serum retinol (SROL) concentration < 0.70 µmol/L (< 20 µg/dl) or abnormal CIC, in the developing world,* of whom 4.4 million have xerophthalmia (X)**(table 1) [15] . Nearly half of the world's xerophthalmic children reside in South and Southeast Asia, of whom over 85% live in India. These numbers are comparable in magnitude to those of a decade ago [16] despite considerable population growth during the interim, which probably reflects degrees of success in vitamin A deficiency control. Figure 1 presents a map of regional preschool child risk of both xerophthalmia (all active stage, X), at cut points of 0.5% and 1.5%,*** and vitamin A deficiency (< 0.70 μmol/L for serum retinol or abnormal impression cytology) [15] using 15% as a prevalence cut point as recently adapted by the IVACG [2] . Accordingly, highest risk countries where xerophthalmia affects > 1.5% and vitamin A deficiency > 15% of young children include especially India, and countries in the northeast and Horn of Africa. Several countries have lower rates of xerophthalmia with persistent (biochemical) vitamin A deficiency (e.g., Bangladesh and Nepal), possibly reflecting known high efficacy of vitamin A capsule distribution in preventing xerophthalmia (≈ 90%) but relative inability to raise and sustain adequate serum retinol concentrations 
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in populations [17] . Linking vitamin A distribution, for example, with the Expanded Programme for Immunization (EPI) and National Immunization Day (NID) activities [18] has achieved considerable success in many countries in raising once-annual vitamin A coverage, which may have lowered the xerophthalmia burden further in the past few years. Chronic vitamin A deficiency appears to affect women during their reproductive years. Recently, it has been estimated that nearly 20 million pregnant women in a given year have low vitamin A status (with SROL or breast milk vitamin A concentrations < 1.05 µmol/L), of whom 7 million are deficient (concentrations < 0.70 µmol/L) and 6 million experience gestational night blindness (XN) [15] (table 2) . By these estimates, nearly two-thirds of the world's night-blind women live in South and Southeast Asia, of whom 75% live in India, although this provisional global distribution may be reflecting, to a degree, more adequate population assessment of maternal XN in India than other high-risk countries at present for which conservative assumptions were applied to obtain numbers of cases.
The large numbers of vitamin A-deficient pregnant women also suggest that interim school-aged and ado- X ≥ 1.50% and VAD ≥ 15% X ≥ 1.50% or VAD ≥ 15% X 0.50% to 1.49% and VAD ≤ 15% X < 0.50% and VAD < 15% S81 lescent years, at least among females, are ones likely to harbor significant, but as yet little appreciated, vitamin A deficiency.
Vitamin A deficiency disorders (VADD)
Health consequences attributable to vitamin A deficiency are collectively defined as vitamin A deficiency disorders, or VADD ( fig. 2 ), as recently set forth in the Annecy Accords [2] . These conditions range from ocular manifestations of xerophthalmia, including its blinding sequellae, to less specific disorders of impaired mechanisms of host resistance, severe infectious illnesses, poor growth, and mortality attributable to vitamin A deficiency in a population [2] . The stages of xerophthalmia, owing to their specificity, comprise both VADD and indicator variables for assessing prevalence and severity of deficiency in a population. On the other hand, biochemical concentrations of retinol in plasma, breast milk, or the liver below conventional cutoffs serve to indicate status, but, alone, do not constitute VADD. Long-term inadequate dietary intake influences vitamin A status and is a strong determinant of VADD [19, 20] , but, by itself, assessed dietary vitamin A intake serves neither as a status indicator nor disorder. The inclusive, but plausible, evidence-based definition of VADD provides a framework for improving status assessment, better understanding vitamin A deficiency-disease relationships and their associated health burden, and characterizing public-health benefits of prevention.
VADD in preschool children
Preschool children in poor societies are especially susceptible to vitamin A deficiency and its health consequences (xerophthalmia, infection, poor growth, anemia, mortality) due to high nutrient demand to support growth, frequent exposure to infection and nutritionally demanding illnesses, and chronic lack of an adequate diet and health care.
Xerophthalmia
Xerophthalmia remains the leading known cause of preventable blindness in young children [1, 21] . Corneal xerosis, ulceration, and necrosis (keratomalacia) are the result of severe vitamin A deficiency, often precipitated by severe infection such as measles [22] in the presence of wasting malnutrition [23] . Corneal xerophthalmia, however, is rare, due to combined effects of low incidence and high case fatality, and appears to be in decline [24] . Milder, non-blinding xerophthalmic stages include night blindness, reflecting impaired dark adaptation due to lack of vitamin A in rod photoreceptors, and Bitot's spots arising from keratinizing metaplasia of the bulbar conjunctiva [3] . Both conditions are indicative of moderate to severe vitamin A deficiency, with affected children usually having serum retinol concentrations below the conventional cutoff of 0.70 µmol/L [25] . Xerophthalmia responds to high-potency vitamin A treatment,* with night blindness typically resolving within 24-48 hours, Bitot's spots responding within several days to a few weeks, and corneal lesions beginning to heal within 2-3 days [3] .
Infectious diseases
Vitamin A deficiency increases susceptibility to infection, which, in turn, may further aggravate the deficient state, revealing a classical "synergism" described by Scrimshaw, Gordon, and Taylor [27] almost four decades ago that our increased understanding of mechanisms continues to support [28] [29] [30] . Children with mild xerophthalmia ( night blindness or Bitot's spots) exhibit impaired antibody [31] and cell-mediated [32] immunity, elevated acute phase plasma proteins suggestive of infection [33] , poor growth [34, 35] , in addition to increased risks of diarrhea [36, 37] , respiratory disease [36] , and mortality [38] . Conversely, children with diarrhea and lower respiratory infection living in areas of endemic vitamin A deficiency are more likely to develop xerophthalmia [39] . The reverse causality is plausible given high urinary losses of retinol following enteric and respiratory infections [30] and acute depression of circulating retinol in response to infection [30] . These responses, coupled with decreased vitamin A intake and absorption, act to deplete tissue retinol that can result in health consequence.
Vitamin A supplementation has been shown to reduce the severity of measles, malaria, and diarrhea. Clinical trials have shown that supplementation can reduce the severity of measles complications [40] and markedly lower case fatality, by ≈ 50% [1] . Infection with Plasmodium falciparum depresses serum retinol and retinol binding protein concentrations during the acute response to infection [41] , which may exacerbate disease. In a randomized field trial in Papua New Guinea, supplementing preschool children with 200,000 IU vitamin A every 4 months reduced falciparum malarial episodes by 30%, as well as circulating parasite densities and rates of splenomegaly compared to placebo receipt [42] . Because not all studies have shown similar effects [43] , additional studies are needed to confirm the prophylactic value of vitamin A against falciparum malaria.
Diarrhea and shigella dysentery are associated with increased urinary losses of retinol [30, 44] , which may exacerbate infection. Vitamin A supplementation has been shown to reduce the severity of diarrhea or dysentery in undernourished populations [45] [46] [47] , presumably by enhancing epithelial repair and function in the intestine and helping to conserve body stores of vitamin A. On the other hand, despite known damage that experimental vitamin A deficiency causes to respiratory epithelium and local secretory defenses in animals [48] , and increased urinary retinol loss during acute lower respiratory infections (ALRI) [1, 30] and higher risks of respiratory infection in vitamin A-deficient children [1] , high-potency vitamin A use has usually been found to be ineffective in reducing the incidence, duration, severity, or case fatality of ALRI in preschool children [45, 49] . In some trials, signs and symptoms of increased respiratory disease have followed vitamin A supplementation [47, 50, 51] , possibly reflecting enhanced immune-mediated airway activity, inflammation, or transient toxicity [30, 51] . Adverse effects of vitamin A supplementation, when reported, have tended to occur surprisingly more frequently in adequately nourished groups of infants and children, whereas therapeutic and prophylactic benefit accrues more visibly in poorly nourished or diseased individuals or populations [1, 47, 50, 52, 53] . Mechanisms to adequately explain these interactions are presently lacking.
Poor growth
Vitamin A is essential for mammalian growth [54] . Although vitamin A is doubtless needed for child growth, isolating its effects amidst other growthlimiting insults (coexisting nutrition deficiencies or infection) has proven difficult. Children with mild xerophthalmia are often stunted [1, 37] and may exhibit some degree of wasting [37, 55] . Incident or chronic mild xerophthalmia is associated with slowed pon-dostatural growth, but the dominating height deficit observed in cross-sectional studies may, in part, result from more complete catch-up in weight than height during recovery from one or more xerophthalmic episodes in the preschool years [34] . The more severe the vitamin A deficiency or illness, the greater the chances that supplementation will improve either linear [35, 56, 57] or ponderal [40, [57] [58] [59] [60] growth. Effects where present, however, may be seasonal [35, 59] , age-or sex-specific [57, 58, 60, 61] , and may be modulated by disease factors, such as duration of respiratory infection [62] or intestinal worm burden [61] , which makes the growth response difficult to predict as a public health benefit of vitamin A deficiency control. The oftennoted lack of impact of vitamin A supplementation on child growth in diverse populations [63] [64] [65] may reflect relative adequacy of pre-existing dietary vitamin A intake to support levels of growth possible in a particular setting, modulating effects by other nutrition deficiencies on growth or vitamin A utilization, persistent infection, adequacy of health care, or study design factors that could mask effects (e.g., exclusion criteria, duration of study).
Anemia
A link between anemia and night blindness has been recognized since the late 19th century [66] . Since then, children with xerophthalmia have been noted to be anemic, and experimentally vitamin A-depleted animals have been found to lack hematopoietic capacity. Childhood surveys in undernourished populations of South Asia, Africa, and Central America have noted correlations (r) of ≈ 0.20-0.50 between hemoglobin and plasma retinol concentrations. The association appears causal as trials among preschool-and schoolaged children have usually, though not always, reported increases in hemoglobin (Hb) concentrations following vitamin A supplementation, ranging from 9 to 21 g/L, compared with controls [66, 67] . Hematopoietic responses to vitamin A are likely influenced by initial vitamin A, iron, and parasite status of children; dosage of vitamin A; duration of supplementation; and other complex physiologic factors. Anemia of vitamin A deficiency may be attributed to several plausible mechanisms that may respond to improved vitamin A nutriture, including impaired mobilization and transport of body iron, disturbed erythropoietin synthesis, defective hematopoiesis in bone marrow, or sequestration of iron in response to acute and chronic infection [66, 67] .
Child mortality
There is consistent evidence that an increased intake of vitamin A, achieved by supplementation or food fortification, can improve survival of older infants and preschool aged children. On the other hand, vitamin A supplementation below 6 months of age may or may not improve early infant survival, which is presently driving public health research.
Infants and children 6-72 months of age. Motivated by observations in the late 1970s of higher mortality risk among mildly xerophthalmic children [38] , eight community trials involving more than 177,000 preschool aged children were carried out in the 1980s and 1990s in Southern Asia and Africa to examine the effects of vitamin A supplementation in reducing mortality among preschool children. Six trials observed statistically significant reductions in mortality from all causes in vitamin A-supplemented children compared with children in control groups. Interventions that have been tested include periodic high-potency vitamin A delivery (200,000 IU in infants > 12 months old, halfdose in infants 6-11 months old, every 4-6 months), which reduced death rates by 19-34% [68] [69] [70] [71] ; weekly low-dose (8,000 IU) vitamin A delivery that lowered mortality by 54% in one trial [72] ; and fortification of monosodium glutamate, a flavor enhancer, that reduced mortality by 45% when consumed by preschoolers at a level that provided approximately one-third of a recommended dietary allowance (RDA) [56] (fig. 3 ). The findings suggest that consuming vitamin A in smaller, more frequent doses through diet or supplements could be more protective, albeit programmatically more demanding, than periodic use of high-potency vitamin A. Although two field trials failed to find a significant impact of vitamin A on survival [73, 74] , published meta-analyses have suggested that the effects of these trials are compatible with an underlying reduction in preschool child mortality of 23-34% [1, 75, 76] . The findings are most relevant to underdeveloped settings where children are chronically exposed to undernutrition, where high levels of morbidity are coupled with inadequate health care and other social services, and where a resultant excess of childhood mortality exists.
Infants < 6 months of age. In infants under 6 months of age living in high risk conditions, improved survival with vitamin A may depend on several key factors, such as age at dosing, size of dosage, dominant causes of mortality, and possibly, body size of the infant. Placebo-controlled field trials in Nepal, Ghana, Peru, and India have, for example, failed to find an overall survival benefit among infants dosed at varying ages during the first 6 months of life. In the Nepal study, infants given placebo or 50,000 IU vitamin A (if < 1 month of age) or 100,000 IU (if 1-5 months of age) during four monthly home visits showed no differences in mortality [52] . Similarly, in the other countries, no mortality differential was observed among infants given placebo versus 25,000 IU vitamin A at each diphtheria-pertussis-tetanus (DPT) vaccine visit carried out at approximately 6, 10, and 14 weeks of age [77] . Dosing mothers with vitamin A has also achieved little improvement in early infant survival. Again, in Nepal, a randomized trial found that dosing women each week with placebo versus an equivalent of a maternal RDA of vitamin A, either preformed or as beta-carotene, had no overall impact on infant mortality [78] , although subgroup analyses revealed some survival benefit to infants born of night-blind mothers [79] .
The above findings suggest neither maternal nor direct dosing of infants < 6 months of age with vitamin A can improve infant survival, although liver vitamin A stores are likely to benefit for meeting subsequent demands [80] [81] [82] . However, two recent randomized, placebo-controlled trials in Indonesia [83] and southern India [84] challenge this conclusion. In both trials, infants dosed with approximately 50,000 IU of vitamin A shortly after birth, rather than later in neonatal or postneonatal life, experienced significant 64% and 22% reductions in mortality, respectively, relative to controls ( fig. 4, panels A and B) . Mechanisms for how vitamin A given at birth could reduce risk of death not achieved in later months or via the mother are likely to be complex, but could involve direct effects of the vitamin on organ development and maturity in the newborn that could affect subsequent function and health. For example, experimental studies in various species show that vitamin A can alter maturation, repair, or function of the immature pulmonary tract [85, 86] , cardiovasculature [87, 88] , immune system [89] , and gastrointestinal tract [90] -problems that would be more prevalent and acute in preterm infants, who are also at higher risk of having extremely low vitamin A stores [91] . Notably, in the South Indian trial, the entire effect of vitamin A dosing on mortality occurred in newborns of low birth weight (< 2500 g), some proportion of whom would have been born preterm and developmentally less mature than term infants. Vitamin A-dosed newborns were also half as likely as controls to be carrying pneumococcal bacteria in nasopharyngeal secretions between 2 and 4 months of age (odds ratio [OR] = 0.51; 95% CI: 0.28-0.92) [92] , suggesting reduced bacterial adherence, seen previously in vitamin A-deficient children [93] , and improved resistance to pneumonia in the first half of infancy.
VADD in pregnant and lactating women
Evidence is emerging to reveal that maternal vitamin A deficiency is associated with significant health risks. Night blindness is a xerophthalmic symptom that can affect 5-15% of pregnant women in an undernourished population. Maternal history of night blindness also serves as an indicator of vitamin A deficiency among women of reproductive age and in the community, with a minimum cutoff set at 5% [4] . In Nepal, mothers reporting to be night blind in the third trimester were more likely to be anemic (odd ratio [OR] = 3) and report symptoms of urinary or reproductive tract infection (OR = 2.1), diarrhea or dysentery (OR = 3.4), or nausea, vomiting, and poor appetite (OR = 2.1) [94] . Cases were also more likely to have reported symptoms consistent with urinary/reproductive tract infection (OR = 1.9), upper gastrointestinal upset (OR = 2.7), and pre-eclampsia 2-3 months before their first report of night blindness [94] . These cases were at about the same mid-gestational age as mothers from another prospective series, who themselves developed night blindness later in pregnancy and who were found to have lower mid-pregnancy serum retinol, retinolbinding protein, and transthyretin concentrations than women never experiencing the condition [95] . While infection may have contributed to the hyporetinolemia [30] , it is likely that chronic vitamin A deficiency preceded infection, because it has been observed that night blindness tends to recur during repeated pregnancies [96] . Studies from Nepal have also revealed a four-fold higher mortality among women who had developed night blindness during pregnancy for up to 2 years following the index pregnancy outcome, primarily associated with infectious causes [97] . Thus, maternal night blindness appears to flag mothers who are vitamin A deficient and at increased risk of poor health possibly due, in part, to underlying vitamin A deficiency and other associated causes.
Milder, non-xerophthalmic vitamin A deficiency in mothers also appears to contribute to anemia. In the plains of Nepal, 14% of all maternal anemia (Hb < 110 g/L) and 29% of moderate-to-severe anemia (Hb < 90 g/L) could be attributed to low vitamin A status (SROL < 1.05 μmol/L) [98] . Low-dose, daily supplementation of pregnant Indonesian women with vitamin A (2400 μg retinol equivalents [RE]) for 2 months raised Hb by 6 g/L over placebo recipients, versus a 10 g/L increment obtained with iron alone (60 mg/d) and a 15 g/L increment when both iron and vitamin A were given, reflecting a role for vitamin A alone and in combination with iron in preventing anemia [99] . Similar additive effects of vitamin A on hema- Panel B: Survival curves from birth through 6 months of age for South Indian newborns randomized to receive vitamin A (24,000 IU on 2 consecutive days) or placebo. Spread between lines represents a 22% reduction (p = 0.02) in mortality attributed to vitamin A receipt. Source: Rahmathullah L, et al. [84] . Reprinted from the British Medical Journal, with permission from the BMJ Publishing Group. tologic indicators in pregnancy have been observed elsewhere [66, 67] . Vitamin A may also contribute to overall maternal health and survival. A large trial among approximately 22,000 pregnant Nepalese women observed reductions of 40% and 49% in mortality related to pregnancy through 12 weeks post-partum among those supplemented weekly with an RDA equivalent of preformed vitamin A (7000 μg RE) or beta-carotene (42 mg), respectively [100] . "Verbal autopsy" interviews conducted with family members of deceased women were inconclusive about causes of death most affected by the intervention, with some evidence of lower mortality associated with infection (by 22%, not significant) and various obstetric conditions (by 27%, not significant). Vitamin A-supplemented women reported approximately 10% fewer days of symptomatic morbidity in the third trimester of pregnancy, labor of about 1 hour shorter duration, and, in the 6 months following birth, approximately 15% fewer weekly episodes of diarrhea (OR = 0.80 to 0.87) [101] .
It is plausible to suspect that vitamin A deficiency may predispose mothers to infection [102] . A trial in London in 1931 reported 77% and 38% reductions in incidence of puerperal sepsis and milder postpartum febrile episodes, respectively, among mothers who took a vitamin A (and vitamin D) preparation daily (equivalent to approximately 1 oz cod liver oil) from the last month of pregnancy through delivery [103] . This finding was recently corroborated by a 2 × 2 factorial trial that evaluated health effects of daily zinc or vitamin A (2400 µg retinol equivalents) supplement use among 680 Indonesian mothers from the first trimester of pregnancy through the early postpartum period. Vitamin A recipients were less likely to report at least 1 day of post-partum fever (> 38°C) (1.2%) than women not receiving vitamin A (5.6%) (relative risk [RR] = 0.22; 95% CI .08-.65) [104] . Zinc supplementation had no effect, nor was there interaction of the two supplements on puerperal fever. Additional trials are currently underway (e.g., in Bangladesh) to further evaluate effects of low-dose maternal vitamin A supplementation on pregnancyrelated morbidity and mortality.
Prevention of vitamin A deficiency
Vitamin A deficiency can be controlled as a public health problem by maintaining adequate intakes of the nutrient in high-risk groups through direct supplementation, fortification, agronomic programs, marketing, and educational efforts to improve diet. The epidemiology of VADD, particularly well-described for mild xerophthalmia [1, 105] , can provide a basis for targeting and program design. For example, the prevalence of mild xerophthalmia in children may increase seasonally with cases tending to cluster by province, village, and within households [106] . Taking both of these time and location factors into consideration, six monthly, high-potency vitamin A supplements (e.g., 200,000 IU for children ≥ 12 months; half this dose at 6-11 months of age) [107] should be timed to precede the peak xerophthalmia season by at least a month. High vitamin A supplementation coverage has been achieved in recent years through the conduct of well-coordinated campaigns occurring every six months. National Immunization Days (NIDS) that include polio vaccination, for example, have provided opportunities to cover preschoolers once a year [18] . Often NIDS-based vitamin A delivery has been complemented by vitamin A distribution through other child health or stand-alone campaigns during alternating six-month periods [26] . For smaller programs, knowledge that VADD clusters by a factor of ~2 within villages and a factor of 7-10 among siblings of the same household [106] , who tend to consume diets similar to cases [108] , suggests that health care providers should do the following: (1) treat the xerophthalmic child (or night-blind mother) [3] ; (2) dose prophylactically preschool-aged siblings of the case (or young children of a night-blind mother); (3) evaluate and provide dietary advice to the family of a case; and (4) broadly implement supplementation, gardening, or counseling programs in communities from which cases originate.
Nutrition education, social marketing, and other food-based approaches can be equally developed from epidemiologic evidence. Guiding mothers to breast-feed infants through the third year of life rests on a consistent association of protection against xerophthalmia [1, 109] . A diet that regularly provides preformed vitamin A or provitamin A carotenoids is strongly associated with protection from VADD among children [19, 20, 55] and pregnant women [94] . Thus, dietary counseling, guided by seasonal availability and cost, should strive toward higher consumption of vegetable, fruit, and animal sources of vitamin A. Recently it has been amply demonstrated that provitamin A carotenoids from plant foods, and especially dark green leaves, are bioconverted to vitamin A much less efficiently (≥12:1) than previously thought (6:1) [110, 111] . While such evidence should not dampen efforts to promote intakes of vegetables and fruit to improve vitamin A status, it does help explain the persistence of vitamin A deficiency amidst dietary ecologies of seasonally available provitamin A-rich foods and highlights a preference for some preformed dietary vitamin A, either from animal foods or through fortification.
Vitamin A-fortified food-aid commodities, such as those distributed as part of the United States Public Law 480 Program, often, by program design, end up "self-targeting" vulnerable groups, including those at risk of VADD during periods of nutrition stress [112] .
Attention is increasingly being paid to developing, evaluating, and promoting vitamin A-fortified commercial food products that do, or could, penetrate markets of the poor, such as sugar [113] , non-refrigerated margarine [114] , wheat flour [115] , and beverages [116] , among others. Although socioeconomic indicators generally show poor specificity with vitamin A status, communities of low socioeconomic status nonetheless tend to harbor significant vitamin A deficiency in atrisk countries [1] , making such fortification projects "progressive," as long as the products are priced to sell in rural and other markets serving the poor. Development of lowest-cost packaging may prove to be essential for successful vitamin A fortification of products in low-end markets.
Conclusion
Vitamin A deficiency remains widely prevalent in the developing world. In children, it leads to VADDs, which include xerophthalmia with its potential to blind; impaired host resistance to infection with consequent increased risks of severe diarrhea, measles, malaria, and other febrile illnesses; poor growth; and mortality. Prevention of vitamin A deficiency and its disorders can have a marked effect on child health and survival. Although involving seemingly more complex explanatory mechanisms, vitamin A supplementation at birth may improve chances of survival during early infancy. In recent years, public health attention has been extended to reveal a sizeable burden of vitamin A deficiency among women during pregnancy and postpartum periods, with a potentially significant impact of prevention on maternal morbidity and mortality. These latter findings, while requiring confirmation, suggest a need to develop effective preventive approaches that cover these previously unappreciated target groups, thereby widening the proportion and numbers in need of vitamin A in undernourished societies. Dietary policies to prevent vitamin A deficiency should be evidencebased, marketed to high-risk populations, adequate in coverage, and flexible in program content.
